- Home
- DGICB vs IOVA Comparison
DGICB vs IOVA Comparison
Compare DGICB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- IOVA
- Stock Information
- Founded
- DGICB 1986
- IOVA 2007
- Country
- DGICB United States
- IOVA United States
- Employees
- DGICB N/A
- IOVA N/A
- Industry
- DGICB Property-Casualty Insurers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGICB Finance
- IOVA Health Care
- Exchange
- DGICB Nasdaq
- IOVA Nasdaq
- Market Cap
- DGICB 605.9M
- IOVA 597.7M
- IPO Year
- DGICB N/A
- IOVA N/A
- Fundamental
- Price
- DGICB $16.80
- IOVA $1.75
- Analyst Decision
- DGICB
- IOVA Buy
- Analyst Count
- DGICB 0
- IOVA 10
- Target Price
- DGICB N/A
- IOVA $12.22
- AVG Volume (30 Days)
- DGICB 695.0
- IOVA 19.7M
- Earning Date
- DGICB 07-24-2025
- IOVA 05-08-2025
- Dividend Yield
- DGICB 3.93%
- IOVA N/A
- EPS Growth
- DGICB 1206.68
- IOVA N/A
- EPS
- DGICB 2.03
- IOVA N/A
- Revenue
- DGICB $993,637,805.00
- IOVA $212,679,000.00
- Revenue This Year
- DGICB $3.27
- IOVA $83.64
- Revenue Next Year
- DGICB $4.01
- IOVA $70.34
- P/E Ratio
- DGICB $10.13
- IOVA N/A
- Revenue Growth
- DGICB 5.29
- IOVA 11070.12
- 52 Week Low
- DGICB $10.75
- IOVA $1.64
- 52 Week High
- DGICB $18.50
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- DGICB 42.24
- IOVA 33.50
- Support Level
- DGICB $15.86
- IOVA $1.70
- Resistance Level
- DGICB $18.47
- IOVA $1.87
- Average True Range (ATR)
- DGICB 0.22
- IOVA 0.15
- MACD
- DGICB -0.08
- IOVA 0.02
- Stochastic Oscillator
- DGICB 36.02
- IOVA 27.50
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.